1-7 of 7
W. Clay Gustafson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3597: Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor

Elena S. Koltun, Meghan A. Rice, W. Clay Gustafson, David Wilds, Jingjing Jiang, Bianca J. Lee, Zhengping Wang, Stephanie Chang, Mike Flagella, Yunming Mu, Nuntana Dinglasan, Nicole Nasholm, James W. Evans, Yingyun Wang, Kyle Seamon, Yang Liu, Cristina Blaj, John Knox, Rebecca Freilich, Elsa Quintana, Jim Cregg, Alun Bermingham, Adrian L. Gill, Jacqueline Am Smith, Mallika Singh
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3597.
https://doi.org/10.1158/1538-7445.AM2022-3597
Published: 15 June 2022
View articletitled, Abstract 3597: Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor
Journal Articles

Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers

Adam J. Wolpaw, Richard Bayliss, Gabriele Büchel, Chi V. Dang, Martin Eilers, W. Clay Gustafson, Gwenn H. Hansen, Natalia Jura, Stefan Knapp, Mark A. Lemmon, David Levens, John M. Maris, Ronen Marmorstein, Steven J. Metallo, Julie R. Park, Linda Z. Penn, Michael Rape, Martine F. Roussel, Kevan M. Shokat, William P. Tansey, Kliment A. Verba, Seychelle M. Vos, William A. Weiss, Elmar Wolf, Yaël P. Mossé
Journal: Cancer Research
Series: Author Choice
Cancer Res (2021) 81 (7): 1627–1632.
https://doi.org/10.1158/0008-5472.CAN-20-3108
Published: 01 April 2021
View articletitled, Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers
Open the PDF for Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers in another window
Journal Articles

Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface

Jessica Koach, Jessica K. Holien, Hassina Massudi, Daniel R. Carter, Olivia C. Ciampa, Mika Herath, Taylor Lim, Janith A. Seneviratne, Giorgio Milazzo, Jayne E. Murray, Joshua A. McCarroll, Bing Liu, Chelsea Mayoh, Bryce Keenan, Brendan W. Stevenson, Michael A. Gorman, Jessica L. Bell, Larissa Doughty, Stefan Hüttelmaier, Andre Oberthuer, Matthias Fischer, Andrew J. Gifford, Tao Liu, Xiaoling Zhang, Shizhen Zhu, W. Clay Gustafson, Michelle Haber, Murray D. Norris, Jamie I. Fletcher, Giovanni Perini, Michael W. Parker, Belamy B. Cheung, Glenn M. Marshall
Journal: Cancer Research
Series: Author Choice
Cancer Res (2019) 79 (21): 5652–5667.
https://doi.org/10.1158/0008-5472.CAN-19-1112
Published: 01 November 2019
View articletitled, Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
Open the PDF for Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface in another window
Includes: Supplementary data
Journal Articles

Abstract B78: Targeting the translational apparatus in MYCN-driven medulloblastoma

Justin G. Meyerowitz, W. Clay Gustafson, Erin Nekritz, Fredrik Swartling, Kevan M. Shokat, Davide Ruggero, William A. Weiss
Journal: Cancer Research
Cancer Res (2014) 74 (20_Supplement): B78.
https://doi.org/10.1158/1538-7445.PEDCAN-B78
Published: 09 October 2014
View articletitled, Abstract B78: Targeting the translational apparatus in MYCN-driven medulloblastoma
Journal Articles

Abstract PR08: Drugging MYCN protein stability through an allosteric transition in Aurora kinase A

W. Clay Gustafson, Justin G. Meyerowitz, Erin A. Nekritz, Elise Charron, Katherine K. Matthay, Nicholas T. Hertz, Martin Eilers, Kevan M. Shokat, William A. Weiss
Journal: Cancer Research
Cancer Res (2014) 74 (20_Supplement): PR08.
https://doi.org/10.1158/1538-7445.PEDCAN-PR08
Published: 09 October 2014
View articletitled, Abstract PR08: Drugging MYCN protein stability through an allosteric transition in Aurora kinase A
Journal Articles

Abstract 4622: Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition.

Alexandre Puissant, Stacey M. Frumm, Gabriela Alexe, Christopher F. Bassil, Jun Qi, Yvan H. Chanthery, Erin A. Nekritz, Rhamy Zeid, W. Clay Gustafson, Patricia Greninger, Matthew J. Garnett, Ultan McDermott, Cyril H. Benes, Andrew L. Kung, William A. Weiss, James E. Bradner, Kimberly Stegmaier
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 4622.
https://doi.org/10.1158/1538-7445.AM2013-4622
Published: 15 April 2013
View articletitled, Abstract 4622: Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition.
Journal Articles

Abstract 1558: Paracrine signaling through Mycn enhances tumor-vascular microenvironment in neuroblastoma

Yvan H. Chanthery, W. Clay Gustafson, William A. Weiss
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 1558.
https://doi.org/10.1158/1538-7445.AM2011-1558
Published: 15 April 2011
View articletitled, Abstract 1558: Paracrine signaling through Mycn enhances tumor-vascular microenvironment in neuroblastoma